RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+10.77%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$4.58B
AUM Growth
+$4.58B
(-2.1%)
Cap. Flow
+$43.2M
Cap. Flow
% of AUM
0.94%
Top 10 Holdings %
Top 10 Hldgs %
23.53%
Holding
172
New
18
Increased
60
Reduced
32
Closed
20
Top Buys
| 1 |
Immunocore
IMCR
|
$97.6M |
| 2 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$73M |
| 3 |
Bolt Biotherapeutics
BOLT
|
$51.3M |
| 4 |
Cullinan Oncology
CGEM
|
$44.8M |
| 5 |
AstraZeneca
AZN
|
$32.3M |
Top Sells
| 1 |
Neurocrine Biosciences
NBIX
|
$54.5M |
| 2 |
UnitedHealth
UNH
|
$48.4M |
| 3 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$47.9M |
| 4 |
Centene
CNC
|
$43.8M |
| 5 |
Immunovant
IMVT
|
$41.2M |
Sector Composition
| 1 | Healthcare | 93.74% |
| 2 | Consumer Staples | 1.75% |
| 3 | Industrials | 0.62% |
| 4 | Financials | 0.12% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRTX
26
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $55.4M | 1.21% | 323,647 -49,505 | -13% | -$8.48M |
|
27
Teleflex
TFX
$5.59B
| $54M | 1.18% | 130,000 | – | – |
|
|
28
Bolt Biotherapeutics
BOLT
$9.85M
| $51.3M | 1.12% | +1,559,248 | New | +$51.3M |
|
29
Ultragenyx Pharmaceutical
RARE
$2.89B
| $51.2M | 1.12% | 450,000 -116,500 | -21% | -$13.3M |
|
30
Edwards Lifesciences
EW
$47.8B
| $48.7M | 1.06% | 582,000 | – | – |
|
31
Mersana Therapeutics
MRSN
$36.5M
| $44.9M | 0.98% | 2,775,127 +711,460 | +34% | +$11.5M |
|
|
32
Cullinan Oncology
CGEM
$445M
| $44.8M | 0.98% | +1,075,912 | New | +$44.8M |
|
|
KRTX
33
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $44.3M | 0.97% | 368,764 +124,814 | +51% | +$15M |
|
34
Phreesia
PHR
$1.88B
| $44.3M | 0.97% | 850,000 | – | – |
|
|
EAR
35
DELISTED
Eargo, Inc. Common Stock
EAR
| $42.5M | 0.93% | 851,671 -48,329 | -5% | -$2.41M |
|
36
Alnylam Pharmaceuticals
ALNY
$58.5B
| $42.4M | 0.92% | 300,000 -35,000 | -10% | -$4.94M |
|
|
CVET
37
DELISTED
Covetrus, Inc. Common Stock
CVET
| $42M | 0.92% | 1,400,000 +115,000 | +9% | +$3.45M |
|
38
Arvinas
ARVN
$568M
| $41.1M | 0.9% | 621,800 -124,200 | -17% | -$8.21M |
|
39
Encompass Health
EHC
$12.3B
| $41M | 0.89% | 500,000 | – | – |
|
40
Acadia Healthcare
ACHC
$2.12B
| $40M | 0.87% | 700,000 | – | – |
|
41
Penumbra
PEN
$10.6B
| $39.9M | 0.87% | 147,500 -11,500 | -7% | -$3.11M |
|
42
Travere Therapeutics
TVTX
$1.56B
| $36.8M | 0.8% | 1,475,564 +454,564 | +45% | +$11.4M |
|
43
Health Catalyst
HCAT
$239M
| $36.7M | 0.8% | 785,000 | – | – |
|
|
ALLK
44
DELISTED
Allakos
ALLK
| $35.1M | 0.77% | 305,706 -35,794 | -10% | -$4.11M |
|
|
SGEN
45
DELISTED
Seagen Inc. Common Stock
SGEN
| $34.7M | 0.76% | 250,000 | – | – |
|
46
Ardelyx
ARDX
$1.53B
| $34.3M | 0.75% | 5,176,561 +28,449 | +0.6% | +$188K |
|
|
47
AstraZeneca
AZN
$248B
| $32.3M | 0.71% | +650,000 | New | +$32.3M |
|
48
Biogen
BIIB
$19.4B
| $31.8M | 0.69% | 113,500 +13,500 | +14% | +$3.78M |
|
49
Boston Scientific
BSX
$156B
| $30.9M | 0.67% | 800,000 | – | – |
|
50
Guardant Health
GH
$8.41B
| $30.5M | 0.67% | 200,000 | – | – |
|